Summary by Moomoo AI
cspc pharma limited issued a profit warning on October 31, 2024, expecting that as of September 30, 2024, the unaudited comprehensive management accounts for the nine months will show a decrease of approximately 16% in the attributable profit to owners compared to the same period last year. This decrease is mainly due to a decline in pharmaceutical business income, especially in the areas of oncology, cardiovascular, and neurological treatments. Among them, revenue in the oncology treatment area decreased by about 31%, cardiovascular treatment area decreased by about 27%, and the neurological treatment area decreased by about 16% in the third quarter, but overall growth during the reporting period was about 4%. The company emphasizes that these data are preliminary assessments and have not yet been reviewed or audited by auditors. The detailed quarterly performance will be announced around November 15, 2024.
